Bristol Myers Squibb announces that the European Medicines Agency has validated its application for Opdivo + Yervoy as first-line treatment for adult patients with metastatic colorectal cancer with.
Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.
Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy.
Bristol Myers Squibb announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo in combination with cisplatin.